AMW GmbH announced today that Dr. Konstantin Petropoulos has been appointed Chief Executive Officer (CEO) effective March 15, 2021 This expands Dr. Friedrich Tegel and Philipp Karbach to the existing management team.
read moreEmployees of AMW GmbH, a globally active pharmaceutical company based in Warngau, donate the proceeds from a tombola to Holzkirchen.
read moreFirst no company outing, then no Christmas party. Corona has also ruined beautiful traditions at the pharmaceutical developer AMW from Warngau. However, the company has created a replacement. Monday before Christmas, some employees were amazed when two Santas were in front of the camera with a history book to tune in to a Christmas Day via video message.
read moreZentiva will include the leuprorelin implant to its portfolio for selected markets in Western Europe. This implant is another successful product of AMW, developed and produced by AMW The leuprorelin implant for the treatment of prostate cancer received its first marketing authorisation in Germany in 2018 and gained market share quickly.
read moreDr. Wilfried Fischer, founding shareholder of AMW, has retired from the management board and remains associated with the company as an important shareholder. His areas of responsibility will be taken over by the previous Co-Managing Directors Dr. Friedrich Tegel and Philipp Karbach.
read moreMore than 100 people are now employed at the pharmaceutical plant in Warngau. In addition to the implants Goserelin and Leuprorelin and the patches Buprenorphin and Rivastigmine, the specialty pharmaceutical company developed a generic version of MSD’s Nuvaring contraceptive ring to market maturity. AMW is thus setting new standards in contraception. In order to improve its scientific and technical position, AMW has established an advisory board consisting of Dr. Georg Ingram, Dr. Dirk Schrader and Prof. Dr. Gerhard Winter.
read more